On this page · 10 sections
Tagraxofusp
Generic name: tagraxofusp
Brand names: Elzonris
What is tagraxofusp?
Tagraxofusp is used to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults, which is a rare cancer of the blood and/or bone marrow.
tagraxofusp is for use in adults and children who are at least 2 years old.
Tagraxofusp may also be used for other purposes that are not mentioned in this medication guide.
This section was rewritten for readability and reviewed for meaning.
How is tagraxofusp given?
Your doctor will do blood tests to ensure you do not have any conditions that would prevent you from safely using tagraxofusp.
Tagraxofusp is given as an infusion into a vein. A healthcare provider will give you this injection.
You may receive this medicine in a hospital or clinic to quickly address any serious side effects.
You may be given other medications to help prevent serious side effects or an allergic reaction. Continue to take these medicines for as long as your doctor has prescribed.
Tagraxofusp is given in a 21-day treatment cycle. You may need to use the medicine only during the first 5 days of each cycle. Your doctor will decide how long you will be treated with this medicine.
You may need frequent medical tests to ensure this medicine is not causing harmful effects. Your cancer treatments may be delayed or stopped permanently based on the results.
This section was rewritten for readability and reviewed for meaning.
Warnings
Call your doctor right away if you have signs of a serious side effect called capillary leak syndrome: a stuffy or runny nose followed by tiredness or dizziness, thirst, decreased urination, trouble breathing, and sudden swelling or weight gain.
This section was rewritten for readability and reviewed for meaning.
Before taking this medicine
You may need to take a pregnancy test 1 week before starting this treatment.
Tagraxofusp may be harmful to an unborn baby. Use effective birth control to avoid pregnancy while you are using tagraxofusp and for at least 1 week after your last dose.
Do not breastfeed while using this medicine, and for at least 1 week after your last dose.
This section was rewritten for readability and reviewed for meaning.
Tagraxofusp side effects
Get emergency medical help if you have signs of an allergic reaction: hives, rash, itching; mouth sores; sudden warmth or tingly feeling; difficult breathing; swelling of your face, lips, tongue, or throat.
Capillary leak syndrome is a serious side effect of tagraxofusp. Call your doctor right away if you have a stuffy or runny nose followed by:
- tiredness or dizziness;
- thirst;
- decreased urination;
- trouble breathing; and
- sudden swelling or weight gain.
Common side effects of tagraxofusp may include:
- capillary leak syndrome;
- nausea;
- tiredness;
- swelling in your hands or feet;
- fever; or
- weight gain.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
This section was rewritten for readability and reviewed for meaning.
Tagraxofusp dosing information
Usual Adult Dose for Malignant Disease:
12 mcg/kg IV over 15 minutes once daily on Days 1 to 5 of a 21-day cycle until disease progression or unacceptable toxicityComments:-Premedicate patients with an H1-histamine antagonist (e.g., diphenhydramine), H2-histamine antagonist (e.g., ranitidine), corticosteroid (e.g., 50 mg IV methylprednisolone or equivalent) and acetaminophen approximately 60 minutes prior to each infusion.-The dosing period may be extended for dose delays up to Day 10 of the cycle. Use: For the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Usual Pediatric Dose for Malignant Disease:
2 years and older:12 mcg/kg IV over 15 minutes once daily on Days 1 to 5 of a 21-day cycle until disease progression or unacceptable toxicityComments:-Premedicate patients with an H1-histamine antagonist (e.g., diphenhydramine), H2-histamine antagonist (e.g., ranitidine), corticosteroid (e.g., 50 mg IV methylprednisolone or equivalent) and acetaminophen approximately 60 minutes prior to each infusion.-The dosing period may be extended for dose delays up to Day 10 of the cycle. Use: For the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in pediatric patients 2 years and older
What happens if I miss a dose?
Call your doctor for guidance if you miss an appointment for your tagraxofusp injection.
This section was rewritten for readability and reviewed for meaning.
What happens if I overdose?
Since tagraxofusp is administered by a healthcare professional in a medical setting, the chance of an overdose is low.
Follow your doctor's instructions regarding any limitations on food, drinks, or activities.
This section was rewritten for readability and reviewed for meaning.
What other drugs will affect tagraxofusp?
Other drugs may affect tagraxofusp, including prescription and over-the-counter medicines, vitamins, and herbal products. Inform your doctor about all your current medicines and any medicine you begin or stop using.
This section was rewritten for readability and reviewed for meaning.
Frequently asked questions
- What disease is Elzonris (tagraxofusp-erzs) used to treat?
Related medicines
Content is provided for education and is not medical advice. See our medical disclaimer.